12 months
Stage 1-Non-invasive dynamic analysis of PDAC stroma at diagnosis and three months after treatment initiation using imaging markers of vascular behavior and stiffness (DCE-EUS, EUS-EG, MRI-DWI, DCE-MRI)
- 1 RON
-
ActivitiesStage 1-Non-invasive dynamic analysis of PDAC stroma at diagnosis and three months after treatment initiation using imaging markers of vascular behavior and stiffness (DCE-EUS, EUS-EG, MRI-DWI, DCE-MRI) and start of cancer-associated fibroblasts (CAFs) evaluation and direct correlation with progression-free survival and overall survival in PDAC patients. Act.1.1-Development of a structured database, clinical protocols and ethical approvals Act.1.2-Longitudinal evaluation by multimodal EUS imaging and DCE-MRI parameters for PDAC patients Act.1.3-EUS-guided FNB for diagnosis and IHC testing Act.1.4-Start of CAF evaluation on FNB-EUS samples obtained from tumors Act.1.5-Start of prognostic evaluation of CAF expression
12 months
Stage 2-Continuation of the evaluation of cancer-associated fibroblasts (CAFs) and direct correlation with progression-free survival and overall survival in patients with PDAC, reverse-translational evaluation of CAFs
- 1 RON
-
ActivitiesStage 2-Continuation of the evaluation of cancer-associated fibroblasts (CAFs) and direct correlation with progression-free survival and overall survival in patients with PDAC, reverse-translational evaluation of CAFs by targeted imaging, validated by immunohistochemistry and molecular biology techniques (qPCR, microarray) and the realization of the integrated platform for the prediction of the dynamic behavior of PDAC stroma in clinical survival analysis, based on the stratification of the prognosis that includes imaging and pathological variables Act.2.1-Continuation of the longitudinal evaluation by multimodal EUS imaging and DCE-MRI parameters for patients with PDAC Act.2.2-Calculation of the prognostic value of the perfusion and stiffness imaging parameters resulting from A2.1 Act.2.3-Continuation of the eEvaluation of cancer-associated fibroblasts (CAFs) and direct correlation with progression-free survival and overall survival in patients with PDAC Act.2.4-Continuation of CAF evaluation on FNB-EUS samples obtained from tumors Act.2.5-Prognostic evaluation of CAF expression, similar to activity A2.2 Act.2.6-CLE morphometric evaluation of EUS-guided FNB specimens Act.2.7-Ex-vivo molecular CLE (mCLE) based on CAF markers Act.2.8-Development of a framework for predicting the biological behavior of PDAC stroma